Cadila set to introduce cut-price lung cancer drug in India
This article was originally published in Scrip
Privately owned Indian firm, Cadila Pharmaceuticals, is set to launch Mycidac-C (heat-killed mycobacterium w), a desmocollin-3 targeting active immune therapy, for non-small cell lung cancer (NSCLC) on the domestic market.
You may also be interested in...
Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.